HBK Sorce Advisory’s Werewolf Therapeutics HOWL Stock Holding History

HBK Sorce Advisory’s Portfolio HOWL Stock Details HOWL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.99K	Hold	13,227	–	–	﹤0.01%	661
2025 Q4	$8.1K	Hold	13,227	–	–	﹤0.01%	627
2025 Q3	$23.3K	Hold	13,227	–	–	﹤0.01%	615
2025 Q2	$14.4K	Sell	13,227 -314	-2%	-$323	﹤0.01%	590
2025 Q1	$13.2K	Sell	13,541 -1,816	-12%	-$2.38K	﹤0.01%	586
2024 Q4	$22.7K	Buy	15,357 +1,678	+12%	+$3.42K	﹤0.01%	569
2024 Q3	$29K	Buy	13,679 +452	+3%	+$1.03K	﹤0.01%	571
2024 Q2	$32.3K	Hold	13,227	–	–	﹤0.01%	554
2024 Q1	$85.7K	Sell	13,227 -13,227	-50%	-$77.1K	﹤0.01%	585
2023 Q4	$102K	Hold	26,454	–	–	﹤0.01%	546
2023 Q3	$56.6K	Hold	26,454	–	–	﹤0.01%	549
2023 Q2	$80.7K	Hold	26,454	–	–	﹤0.01%	563
2023 Q1	$68.8K	Buy	+26,454	New	+$78.8K	﹤0.01%	564

Other funds holding HOWL

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HBK Sorce Advisory's HOWL Position: Q1 2026 in Review

HBK Sorce Advisory held its Werewolf Therapeutics (HOWL) position steady in Q1 2026 at 13,227 shares worth $8.99K. The position accounts for ﹤0.01% of the portfolio, ranked #661.

HBK Sorce Advisory first reported a position in HOWL in Q1 2023 and has held it in 13 quarters since. The position peaked at $102K in Q4 2023. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

HBK Sorce Advisory held 13,227 shares of Werewolf Therapeutics worth $8.99K as of Q1 2026.
HBK Sorce Advisory left its Werewolf Therapeutics share count unchanged in Q1 2026.
Werewolf Therapeutics made up ﹤0.01% of HBK Sorce Advisory's portfolio in Q1 2026, its #661 holding.
HBK Sorce Advisory first reported a position in Werewolf Therapeutics in Q1 2023 and has held it in 13 quarters since.
HBK Sorce Advisory's Werewolf Therapeutics position peaked at $102K in Q4 2023.
48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on HBK Sorce Advisory's 13F filing for Q1 2026, filed 11 May 2026.